Kite, Gadeta in gamma delta T cell deal

Kite Pharma Inc. and Gadeta B.V. (Utrecht, the Netherlands) partnered to develop T cell therapies that express gamma delta TCRs for hematologic malignancies and solid tumors using Gadeta's platform. Kite, a subsidiary of Gilead Sciences Inc. (NASDAQ:GILD), will obtain an undisclosed upfront

Read the full 424 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE